#UK #Calgary #Decibel Cannabis #General Admission #Standard Issue

Decibel Cannabis Expands UK Market with New Brand Launches

Decibel Cannabis Company Inc. has recently made strides to strengthen its position in the UK cannabis market. The company has announced a brand licensing agreement with Hilltop Leaf Ltd., which will enable the launch of Decibel's flower portfolio under its well-known brands, General Admission and Standard Issue.

Overview of the Launch

As part of this collaboration, Decibel will grant Hilltop a limited license to use its leading Canadian brands. This significant step not only demonstrates Decibel's commitment to expanding its international footprint but also showcases a strategy focused on cultivating global brand recognition and diversifying revenue streams. In the upcoming months, specifically in Q4 2026, Decibel plans to roll out an initial product line consisting of fifteen General Admission and Standard Issue items along with six Hilltop Leaf branded products.

Regulatory Compliance and Supply Chain

What sets this partnership apart is the meticulous attention to regulatory compliance. Both companies are committed to adhering to the stringent regulations laid out for the supply of medical-grade cannabis-based products in the UK. This commitment is further fortified by Decibel’s robust EU GMP certified supply chain, which ensures that finished and packaged medical products are delivered safely and efficiently to the UK market.

Leadership Statements

Kris Newell, the Chief Operating Officer of Decibel, expressed enthusiasm about the collaboration, highlighting that both companies share a strong commitment to quality and consistency. He noted that Decibel has established General Admission as one of Canada's top cannabis brands while Standard Issue is rapidly gaining traction. According to Newell, this partnership with Hilltop will allow both companies to expand their offerings as the UK cannabis market matures.

Hilltop Leaf's Chief Executive Officer, Hamish Clegg, echoed this sentiment, mentioning that after years of business relations, this agreement marks a new chapter of closer collaboration. By uniting their brand strengths and established supply chains, both companies aim to provide patients in the UK with high-quality and consistent cannabis products, tailored to meet the increasing demand.

About Decibel Cannabis Company

Decibel is a Canadian cannabis company recognized for its consumer-driven approach and its strong presence in the adult-use market. It boasts a roster of popular brands such as General Admission, Qwest, and Standard Issue. The company places significant emphasis on innovation, product quality, and effective brand management. In addition to its expertise in Canada, Decibel is actively pursuing growth opportunities in international cannabis markets, supported by facilities in Calgary, Alberta, and provincial partners across Saskatchewan and Ontario.

About Hilltop Leaf Ltd.

On the other hand, Hilltop Leaf Ltd. stands out in the UK medical cannabis sector as a GMP-certified distributor of cannabis-based products. The company prides itself on its compliance with UK regulations and its collaborations with healthcare providers. Hilltop Leaf’s robust network allows for the streamlined distribution of cannabinoids to patients, providing consistent access to high-quality medicinal cannabis products.

Looking Ahead

This partnership not only represents a key milestone for Decibel but also sets the stage for future growth and innovation within the burgeoning UK cannabis market. As both companies prepare to launch their initial product lines later this year, they remain focused on meeting the evolving needs of UK patients, reinforcing their shared commitment to quality, safety, and effective cannabis solutions.

In conclusion, Decibel’s expansion into the UK serves as a testament to its strategic vision and the potential of international markets in the context of cannabis industry dynamics. As the landscape continues to evolve, partnerships like these are likely to play a crucial role in shaping the future of cannabis use in medicine.